APGE
Apogee Therapeutics, Inc.
A clinical-stage biotechnology company developing antibody medicines for inflammatory and immune diseases such as atopic dermatitis, asthma, and COPD. Founded in 2022 as the first spinout from the Waltham, Massachusetts biotech Paragon Therapeutics, it engineers antibodies with longer half-lives so patients may need injections only every few months instead of weekly. The company went public on the Nasdaq in 2023.
CUSIP: 03770N101HealthcareUS1 holder
Recent Activity
2026Q2
1 sell
-109.4K shares
-109.4K shares
Loading more activity...